home news forum careers events suppliers solutions markets expos directories catalogs resources advertise contacts
 
News Page

The news
and
beyond the news
Index of news sources
All Africa Asia/Pacific Europe Latin America Middle East North America
  Topics
  Species
Archives
News archive 1997-2008
 

Annogen signs another collaboration agreement with a tier 1 agricultural firm to research non-coding regulatory DNA using SuRE screening technology


Amsterdam, The Netherlands
April 12, 2022

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.          

Agricultural biotech companies are constantly working on ways to up- or down regulate gene expression to influence traits of crops. Annogen’s services and technology contribute to these efforts by identifying the non-coding elements in the genome that underlie gene expression and repression as well as by performing mutagenesis screens on these elements to analyze the impact of non-coding mutations on gene expression.  

While Annogen has its primary focus on medical applications like cell therapy and drug discovery, it has also already established the applicability of its SuRE™ technology in animals and plants. Joris van Arensbergen, founder and CEO, is pleased with another collaboration in this field: “This projects fits in a trends we are now seeing where people want to apply SuRE™ both to validate AI predictions as well as to provide datasets for AI training purposes. We are very excited to be part of these developments”.

About Annogen               
At Annogen we use our SuRE technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression and we establish databases in which we functionally annotate millions of non-coding sequence variants for their effect on promoter and enhancer activity. This enables researchers to qualitatively interpret non-coding sequence variants in humans, animals and plants in the way we already can for coding sequence variants. For more information, please visit www.annogen.bio.



More news from: Annogen B.V.


Website: https://www.annogen.bio/

Published: April 13, 2022

The news item on this page is copyright by the organization where it originated
Fair use notice

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Archive of the news section


Copyright @ 1992-2024 SeedQuest - All rights reserved